about
Breast necrosis induced by the use of coumadin: case report and review of literatureStudy protocol for the randomised controlled trial: combined multimarker screening and randomised patient treatment with ASpirin for evidence-based PREeclampsia prevention (ASPRE).ASPRE trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history.Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia.[Preterm birth prediction: sequential evaluation of the cervix and the test for phosphorylated protein-1 linked to insulin-like growth factor].Association between fetal fraction on cell-free DNA testing and first trimester markers for pre-eclampsia.Accuracy of second trimester prediction of preterm preeclampsia by three different screening algorithms.ASPRE trial: incidence of preterm preeclampsia in patients fulfilling ACOG and NICE criteria according to risk by the FMF algorithm.Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia.ASPRE trial: performance of screening for preterm pre-eclampsia.Multicenter screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation: comparison with NICE guidelines and ACOG recommendations.Accuracy of competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation.Early screening and prevention of preterm pre-eclampsia with aspirin: time for clinical implementation.Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin on length of stay in the neonatal intensive care unit.Cell-free fetal DNA testing in singleton IVF conceptions.Prediction and prevention of small-for-gestational-age neonates: evidence from SPREE and ASPREScreening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestationUterine Artery Doppler in Screening for Preeclampsia and Fetal Growth Restriction[Cytogenetic analysis of material from spontaneous abortion]Maternal plasma cell-free DNA in the prediction of pre-eclampsiaQuality assessment of uterine artery Doppler measurement in first-trimester combined screening for pre-eclampsiaInfluence of Body Mass Index on Fetal Fraction Increase With Gestation and Cell-Free DNA Test FailurePrediction of preterm pre-eclampsia at midpregnancy using a multivariable screening algorithmExperience and confidence in vaginal breech and twin deliveries among obstetric trainees and new specialists in Australia and New ZealandInter-twin delivery interval, short-term perinatal outcomes and risk of caesarean for the second twinPrediction of Preterm Birth by Maternal Characteristics and Medical History in the Brazilian PopulationSonographic detection of fetal abnormalities before 11 weeks of gestationCranial sonographic markers of fetal open spina bifida at 11 to 13 weeks of gestationPrenatal screening for pre-eclampsia: Frequently asked questionsEarly Diagnosis and Differences in Progression of Fetal EncephaloceleSerum podocalyxin at 11-13 weeks of gestation in the prediction of small for gestational age neonatesEvidence-Based Prevention of Preeclampsia: Commonly Asked Questions in Clinical PracticeSecond and third trimester serum levels of growth-differentiation factor-15 in the prediction of pre-eclampsiaZhang's guidelines vs WHO guidelines for diagnosing labour dystocia
P50
Q28083752-D24EDD7B-58CD-464C-8664-0794DAE5D425Q37063617-4136FF71-8BEF-48FD-8187-B12DF718AB3EQ38636397-987B9F77-05FD-4F29-AB80-5976B9CFB559Q40142875-12062DFA-7F7A-4021-8870-068251FA090DQ44833283-09EB183A-7ED6-40FB-A461-F83329A86345Q47214798-C8860C31-31E7-4909-9DA8-C9DE1EA477E6Q47285655-740228B9-E1FD-4724-B78B-5C136C6EDC24Q47554906-97AA8EE1-3924-43F8-91AE-A8335CB2E8B1Q47692938-5E580F2B-863D-4C84-9F72-19CE5F9537CDQ47752807-C5CD249D-75E0-485E-9FAC-7112965CFF94Q47929307-076C3C70-CC75-493A-BD29-35A00BB773C3Q48017621-BD911CA6-F6B9-4C00-9474-30E360527184Q48099333-4D5FE80F-1DAE-4F30-9529-872841385DF0Q51744328-FA1D859F-359E-4CC3-82AD-C5C274F44955Q52692576-5B72E2DA-64B2-476C-A706-817DC1F8FF6DQ57917842-6C34437B-799B-4AFD-A15C-7CF8247378EBQ57917849-C0E0767B-1092-41D1-9A6A-F96D37E54892Q61989055-A6B58F79-4217-4F60-A549-463DC836FF49Q83308033-5483A1CD-7116-40FF-BD74-2A4A7DBEEA04Q85633853-C69A44DA-E624-4964-84F8-10F39DFE32D7Q89149719-66784C71-A1F3-4ABB-9B18-EE0B51B8B2CBQ89566284-3E8364EA-C03C-48C1-8103-11FAB535F47CQ89987655-5F1F0778-AA16-408B-9FEA-5773BD3B9C44Q90627844-C5CC2E31-9679-44BA-83F6-B2E6E5302F28Q90833728-933DDD08-7C59-455E-82E7-BC563C64FD34Q90992918-65AC5B71-0BC6-4AE9-96C4-5442C3D4631EQ91226628-29579E40-6410-4C8C-9486-81A75B2FE223Q91336522-0C7462C1-E78F-4F9D-871B-74229DDBB116Q92233818-78FB57B0-9E6D-4F39-90FF-C707683F1CEDQ92684031-6721A5FB-1B32-4B59-8296-6F77A58C3D3DQ92886491-7A1D22A1-0A8E-47D2-B782-C9168E512072Q92998262-A1618669-E1B2-4735-9269-4E14DC9B61DFQ94598089-303670A8-5426-4712-B119-33E67FDBBEBCQ95519905-44F5A6BD-2BBF-42D6-BBEB-C6CB4EC24429
P50
description
researcher ORCID ID = 0000-0002-2263-3592
@en
name
Daniel L Rolnik
@ast
Daniel L Rolnik
@en
Daniel L Rolnik
@es
Daniel L Rolnik
@nl
type
label
Daniel L Rolnik
@ast
Daniel L Rolnik
@en
Daniel L Rolnik
@es
Daniel L Rolnik
@nl
prefLabel
Daniel L Rolnik
@ast
Daniel L Rolnik
@en
Daniel L Rolnik
@es
Daniel L Rolnik
@nl
P21
P31
P496
0000-0002-2263-3592